ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1544

Serum Omentin-1 Levels and Metabolic Syndrome in Women with Rheumatoid Arthritis

Alejandra Flores-Chavez1,2, Edsaul Emilio Perez-Guerrero3,4, Melissa Ramirez-Villafaña5,6, Xochitl Trujillo7, Arnulfo Hernan Nava-Zavala8, Teresa Arcelia Garcia-Cobian9, Miriam Fabiola Alcaraz-Lopez10, Mario Salazar-Paramo11, Ernesto German Cardona-Muñoz12, Silvia Elena Totsuka-Sutto12, Laura del Carmen Gonzalez-Lopez5 and Jorge Ivan Gamez-Nava13, 1Unidad de Investigación Biomédica 02 (Unidad de Investigación en Epidemiología Clínica), UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Jalisco, Mexico, 2Doctorado en Ciencias Médicas, Universidad de Colima, Colima, Mexico, 3Unidad de Investigación Biomédica 02 (Unidad de Investigación en Epidemiología Clínica), UMAE, Hospital de Especialidades Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Jalisco, Mexico, 4Doctorado en Farmacología, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Jalisco, Mexico, 5Departamento Medicina Interna-Reumatología, Instituto Mexicano del Seguro Social, Hospital General Regional 110, Jalisco, Mexico, 6Doctorado en Ciencias Médicas, Universidad de Colima, Jalisco, Mexico, 7Centro Universitario de Investigación Biomédica, Universidad de Colima, Colima, Mexico, 8Unidad de Investigación Biomédica 02 (Unidad de Investigación en Epidemiología Clínica), UMAE, Hospital de Especialidades Centro Médico Nacional de Occidente, IMSS, Jalisco, Mexico, 9Unidad de Investigación Cardiovascular, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Jalisco, Mexico, 10Departamento Medicina Interna-Reumatología, Instituto Mexicano del Seguro Social, Hospital General Regional 45, Jalisco, Mexico, 11División de Investigación en Salud, Unidad Médica de Alta Especialidad, Hospital de Especialidades Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Jalisco, Mexico, 12Departamento de Fisiología, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Jalisco, Mexico, 13Unidad de Investigación Biomédica 02 (Unidad de Investigacion en Epidemiología Clínica), UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituo Mexicano del Seguro Social, Guadalajara, Mexico

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: metabolic syndrome and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  Metabolic syndrome (MS) is a common comorbidity in patients with rheumatoid arthritis (RA). Several adipokines have been implied in the pathogenesis of MS on general population and rheumatic inflamatory disorders. Omentin-1 is an adipokine implied in reducing insulin resistance, and improving hypertension and dyslipidemia among general population. Nevertheless, the role of this adipokine in MS is not conclusive and there is no information about the association between serum levels of omentin-1 and the components of MS in RA. In order to test the hypothesis that serum omentin-1 levels are biomarkers of protection for MS the aim of the present study was to evaluate if serum omentin-1 levels are associated with the MS components in patients with RA.

Methods:  In this cross-sectional study we included adult women with established RA (according to 1987 ACR criteria). Exclusion criteria were active infections, cancer, chronic renal failure, hepatic failure or pulmonary fibrosis. Thirty women with RA and MS (RA+MS) according to the NCEP-ATP III criteria were compared with 30 women with RA without MS (RA-MS) matched by range of age. Clinical and epidemiological characteristics were evaluated, as well as disease activity measured by DAS-28 index. Serum omentin-1 levels were determined by ELISA.

Results:  Patients with RA+MS had higher body mass index compared with RA-MS (28.1 vs 24.4 kg/m2, p< 0.001). Serum omentin-1 levels were similar in patients with RA+MS compared with RA-MS (794 vs 941 ng/mL, respectively, p = 0.15). In the correlation between specific components of MS, serum omentin-1 levels correlated with higher diastolic blood pressure (rho= 0.22, p= 0.03) and higher HDL-cholesterol levels (rho= 0.20, p=0.05). After adjusting by age and disease duration, BMI was the major risk factor for MS in this patients (OR= 1.46, 95% CI= 1.06-1.99, p= 0.02), and serum omentin-1 levels did not achieve statistical significance.

Conclusion:  No significant difference in omentin-1 levels in RA patients with and without MS was observed. However serum omentin-1 positively correlated with HDL-cholesterol and diastolic blood pressure. This implies the assumption that this adipokine influences some cardiovascular risk factors and should be evaluated in future studies.


Disclosure: A. Flores-Chavez, None; E. E. Perez-Guerrero, None; M. Ramirez-Villafaña, None; X. Trujillo, None; A. H. Nava-Zavala, None; T. A. Garcia-Cobian, None; M. F. Alcaraz-Lopez, None; M. Salazar-Paramo, None; E. G. Cardona-Muñoz, None; S. E. Totsuka-Sutto, None; L. D. C. Gonzalez-Lopez, None; J. I. Gamez-Nava, None.

To cite this abstract in AMA style:

Flores-Chavez A, Perez-Guerrero EE, Ramirez-Villafaña M, Trujillo X, Nava-Zavala AH, Garcia-Cobian TA, Alcaraz-Lopez MF, Salazar-Paramo M, Cardona-Muñoz EG, Totsuka-Sutto SE, Gonzalez-Lopez LDC, Gamez-Nava JI. Serum Omentin-1 Levels and Metabolic Syndrome in Women with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/serum-omentin-1-levels-and-metabolic-syndrome-in-women-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-omentin-1-levels-and-metabolic-syndrome-in-women-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology